Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Aplexis Inc
Profile last edited on: 12/6/23      CAGE: 8UX62      UEI: Q314G2UGRGL5

Business Identifier: Novel therapies: treat Myeloproliferative Neoplasms (MPNs) and Plek2-overexpressing solid tumor
Year Founded
2021
First Award
2022
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

342 Beverly Drive
Wilmette, IL 60091
   (847) 881-5090
   N/A
   www.aplexis.net
Location: Single
Congr. District: 09
County: Cook

Public Profile

Aplexis -- a startup based on Professor Peng Ji's research at Northwestern University - is an early-stage biopharmaceutical company structured around the development of small molecule inhibitors to treat Myeloproliferative Neoplasms (MPNs) and Plek2-overexpressing solid tumor.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$397,198
Phase II Dollars
$0
Total Awarded
$397,198

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 1 NIH $397,198
Project Title: Developing small molecule inhibitors of Pleckstrin-2 to treat thrombosis

Key People / Management

  Peng Ji -- Founder

  Jing Yang

Company News

There are no news available.